Skip to content

PERNIX THERAPEUTICS HOLDINGS, INC.

Delisted

CIK 1024126fmd_0Y9GDTG1DDEJAFYYN8MCER7D6XManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2010 to Sep 30, 2018, 35 periods

Income Statement · Annual · Millions · USD
Line itemFY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017
Total revenues–616185122176141146
Cost of revenue521063514345
Net interest income0(0)(0)(4)(19)–––
Gross profit–40617811912498101
Realized investment gains (losses)––0400––
Research and development11154861
Selling, general and administrative1522356360979977
Impairment of real estate–0––––––
Operating income1013(2)(54)(30)(101)(140)(56)
Interest expense––––––3837
Interest and investment income–––0000–
Other non-operating income (expense)1(0)(0)7(19)(40)(29)(20)
Income before taxes–13(2)(46)(49)(141)(169)(77)
Income tax expense15(0)(21)(14)700
Net income from continuing operations1113(2)(26)(35)(148)(170)(77)
Net income98(1)(26)(35)(148)(170)(77)
PERNIX THERAPEUTICS HOLDINGS, INC. financial statements · FinancialMD